Effects of dual-action genistein derivatives on relaxation in rat aorta

Journal of Smooth Muscle Research

Volumn 41, Issue 1, 2005, Pages 23-33

  Matsumoto, Takayuki ^a   Kobayashi, Tsuneo ^a   Kikuchi, Toyohiko ^b   Honda, Toshio ^b   Kamata, Katsuo ^a,b  

^a Institute of Physics and Chemistry   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Aorta; Genistein; LPC; NO donor; Rat

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 7 [(4 NITROOXY)BUTYROYL]GENISTEIN; 7 [(4 NITROOXYMETHYL)(ALPHA METHYL)PHENYLPROPANOYL]GENISTEIN; GENISTEIN; GUANYLATE CYCLASE INHIBITOR; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; MALE; NONHUMAN; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENISTEIN; GUANYLATE CYCLASE; LYSOPHOSPHATIDYLCHOLINES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR;

EID: 18244386231     PISSN: 09168737     EISSN: None     Source Type: Journal    
DOI: 10.1540/jsmr.41.23     Document Type: Article

References (40)

1. Bassa, B.Y., Roh, D.D., Vaziri, N.D., Kirschenbaum, M.A. and Kamanna, V.S. (1999). Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCγ-1 and tyrosine kinase-Ras pathways. Am. J. Physiol. 277: F328-F337.
2. Berk, B.C. and Alexander, R.W. (1989). Vasoactive effects of growth factors. Biochem. Pharmacol. 38: 219-225.
3. Busse, R. and Fleming, I. (1996). Endothelial dysfunction in atherosclerosis. J. Vasc. Res. 33: 181-194.
4. Cannon, R.O. 3rd. (1998). Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin. Chem. 44: 1809-1819.
5. Chai, Y.C., Howe, P.H., DiCorleto, P.E. and Chisolm, G.M. (1996). Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271: 17791-17797.
6. 2+ influx, enhanced DNA synthesis and cytotoxicity in cultured vascular smooth muscle cells. Atherosclerosis 112: 69-76.
7. Di Salvo, J., Nelson, S.R. and Kaplan, N. (1997). Protein tyrosine phosphorylation in smooth muscle: a potential coupling mechanism between receptor activation and intracellular calcium. Proc. Soc. Exp. Biol. Med. 214: 285-301.
8. Duarte, J., Ocete, M., Perez-Vizcaino, F., Zarzuelo, A. and Tamargo, J. (1997). Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. Eur. J. Pharmacol. 338: 25-33.
9. Erdman, J.W. Jr. (2000). AHA science advisory: soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 102: 2555-2559.
10. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischmann, G., Hase, T., Montesano, R. and Schweigerer, L. (1993). Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 90: 2690-2694.
11. Fukao, M., Hattori, Y., Kannno, M., Sakuma, I. and Kitabatake, A. (1995). Evidence for selective inhibition by lysophosphatidylcholine of acetylcholine-induced endothelium-dependent hyperpolarization and relaxation in rat mesenteric artery. Br. J. Pharmacol. 116: 1541-1543.
12. Gewaltig, M.T. and Kojda, G. (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res. 55: 250-260.
13. Gimenez, I., Martinez, R.M., Lou, M., Mayoral, J.A., Garau, R.P. and Alda, J.O. (1998). Salidiuretic action by genistein in the isolated, perfused rat kidney. Hypertension 31: 706-711.
14. Gouni-Berthold, I. and Sachinidis, A. (2004). Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis. Curr. Vasc. Pharmacol. 2: 363-370.
15. Hollenberg, M.D. (1994). Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends. Pharmacol. Sci. 15: 108-114.
16. Ignarro, L.J. (2002). Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53: 503-514.
17. Jinsi, A., Paradise, J. and Deth, R.C. (1996). A tyrosine kinase regulates alpha-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta. Eur. J. Pharmacol. 302: 183-190.
18. 2+ mobilization in the aortic endothelium in streptozotocin-induced diabetic and cholesterol-fed mice. Br. J. Pharmacol. 123: 1509-1516.
19. Kanie, N., Matsumoto, T., Kobayashi, T. and Kamata, K. (2003). Relationship between peroxisome proliferator-activated receptors (PPARα and PPARγ) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 140: 23-32.
20. Kapiotis, S., Hermann, M., Held, I., Seelos, C., Ehringer, H. and Gmeiner, B.M. (1997). Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler. Thromb. Vasc. Biol. 17: 2868-2874.
21. Kobayashi, T., Matsumoto, T. and Kamata, K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 131: 231-238.
22. 2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am. J. Physiol. 287: H135-H143.
23. Kugiyama, K., Kerns, S.A., Morrisett, J.D., Roberts, R. and Henry, P.D. (1990). Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344: 160-162.
24. Kume, N., Cybulsky, M.I. and Gimbrone, M.A. Jr. (1992). Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90: 1138-1144.
25. Legradi, A., Chitu, V., Szukacsov, V., Fajka-Boja, R., Szekely Szucs, K. and Monostori, E. (2004). Lysophosphatidylcholine is a regulator of tyrosine kinase activity and intracellular Ca(2+) level in Jurkat T cell line. Immunol. Lett. 91: 17-21.
26. Lloyd-Jones, D.M. and Bloch, K.D. (1996). The vascular biology of nitric oxide and its role in atherogenesis. Annu. Rev. Med. 47: 365-375.
27. Matsumoto, T., Oda, S.I., Kobayashi, T. and Kamata, K. (2004a). Flow-induced endothelium-dependent vasoreactivity in rat mesenteric arterial bed. J. Smooth Muscle Res. 40: 1-14.
28. Matsumoto, T., Wakabayashi, K., Kobayashi, T. and Kamata, K. (2004b). Alterations in vascular endothelial function in the aorta and mesenteric artery in type II diabetic rats. Can. J. Physiol. Pharmacol. 82: 175-182.
29. Ozaki, H., Ishii, K., Arai, H., Kume, N. and Kita, T. (1999). Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 143: 261-266.
30. 2+ influx in vascular smooth muscle cells. Am. J. Physiol. 264: C885-C893.
31. 2+ in rat aorta. Eur. J. Pharmacol. 361: 217-226.
32. 2+ level and contraction on exposure of rat aorta to lysophosphatidylcholine. Eur. J. Pharmacol. 378: 177-186.
33. Suenaga, H. and Kamata, K. (2002). Lysophosphatidylcholine potentiates vascular contractile responses in rat aorta via activation of tyrosine kinase. Br. J. Pharmacol. 135: 789-799.
34. Tasaki, K., Hori, M., Ozaki, H., Karaki, H. and Wakabayashi, I. (2003). Difference in signal transduction mechanisms involved in 5-hydroxytryptamine- and U46619-induced vasoconstrictions. J. Smooth Muscle Res. 39: 107-117.
35. Tham, D.M., Gardner, C.D. and Haskell, W.L. (1998). Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 83: 2223-2235.
36. Toma, C., Jensen, P., Prieto, D., Hughes, A., Mulvany, M.J. and Aalkjaer, C. (1995). Effects of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries. Br. J. Pharmacol. 114: 1266-1272.
37. Triggle, C.R., Hollenberg, M., Anderson, T.J., Ding, H., Jiang, Y., Ceroni, L., Wiehler, W.B., Ng, E.S., Ellis, A., Andrews, K., McGuire, J.J. and Pannirselvam, M. (2003). The endothelium in health and disease-a target for therapeutic intervention. J. Smooth Muscle Res. 39: 249-267.
38. Ullrich, A. and Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
39. Watson, C.L. and Gold, M.R. (1997). Lysophosphatidylcholine modulates cardiac I(Na) via multiple protein kinase pathways. Circ. Res. 81: 387-395.
40. Watts, S.W., Yeum, C.H., Campbell, G. and Webb, R.C. (1996). Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. J. Vasc. Res. 33: 288-298.